-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Clinical Practice Guidelines on Pediatric Venous Thromboembolism (VTE)

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinical Practice (Health Services and Quality), Thromboembolism, Diseases, Study Population
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Room 25 (San Diego Convention Center)
Chair:
Paul Monagle, MD, BS, MSc, FRACP, FRCPA, MB, University of Melbourne Royal Children's Hospital
Disclosures:
No relevant conflicts of interest to declare.

This special education session will give a preview on the revision background, which includes asymptomatic VTE, duration of therapy for provoked and unprovoked VTE, and use of anticoagulants (especially DOACs) in pediatric patients.
Why Revise the Guidelines?

Leslie Raffini, MD

Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA
Asymptomatic VTE in Pediatric Patients

Rukhmi Bhat, MD, MS

Lurie Children's Hospital, Chicago, IL
Duration of Therapy for Provoked and Unprovoked VTE in Pediatric Patients

Marisol Betensky, MD, MPH

Johns Hopkins All Children's Hospital, Saint Petersburg, FL
Use of Anticoagulants in Children

Tina Biss

The Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, ENG, United Kingdom
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>